{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:02:20Z","timestamp":1789398140425,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40801-026-00564-8","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:41:11Z","timestamp":1785318071000},"page":"451-464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA"],"prefix":"10.1007","volume":"13","author":[{"given":"Maria A.","family":"Aleshin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijing","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Friesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"8","key":"564_CR1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","volume":"157","author":"A Jfri","year":"2021","unstructured":"Jfri A, Nassim D, O\u2019Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol. 2021;157(8):924\u201331. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1677.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"564_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB. Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231(2):184\u201390. https:\/\/doi.org\/10.1159\/000431175.","journal-title":"Dermatology"},{"issue":"6","key":"564_CR3","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/bjd.16603","volume":"183","author":"L Matusiak","year":"2020","unstructured":"Matusiak L. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183(6):e171\u20137. https:\/\/doi.org\/10.1111\/bjd.16603.","journal-title":"Br J Dermatol"},{"issue":"1","key":"564_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/jdv.16677","volume":"35","author":"TV Nguyen","year":"2021","unstructured":"Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50\u201361. https:\/\/doi.org\/10.1111\/jdv.16677.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"564_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366\u201376. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1301.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"564_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91\u2013101. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.068.","journal-title":"J Am Acad Dermatol"},{"key":"564_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073753","author":"A Markota \u010cagalj","year":"2022","unstructured":"Markota \u010cagalj A, Marinovi\u0107 B, Bukvi\u0107 Mokos Z. New and emerging targeted therapies for hidradenitis suppurativa. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23073753.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"564_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504370.","journal-title":"N Engl J Med"},{"issue":"11","key":"564_CR9","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.jid.2023.04.009","volume":"143","author":"D Thein","year":"2023","unstructured":"Thein D, Rosen\u00f8 NAL, Maul J-T, Wu JJ, Skov L, Bryld LE, et al. Drug survival of adalimumab, secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3 years of treatment \u2013 a nationwide cohort study. J Invest Dermatol. 2023;143(11):2211-8.e4. https:\/\/doi.org\/10.1016\/j.jid.2023.04.009.","journal-title":"J Invest Dermatol"},{"key":"564_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/ccid.S391356","volume":"16","author":"F Martora","year":"2023","unstructured":"Martora F, Megna M, Battista T, Potestio L, Annunziata MC, Marasca C, et al. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience. Clin Cosmet Investig Dermatol. 2023;16:135\u201348. https:\/\/doi.org\/10.2147\/ccid.S391356.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10476","key":"564_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","volume":"405","author":"R Sabat","year":"2025","unstructured":"Sabat R, Alavi A, Wolk K, Wortsman X, McGrath B, Garg A, et al. Hidradenitis suppurativa. Lancet. 2025;405(10476):420\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(24)02475-9.","journal-title":"Lancet"},{"issue":"3","key":"564_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/jw9.0000000000000159","volume":"10","author":"SV Gangidi","year":"2024","unstructured":"Gangidi SV, Greene RK, Olsen E, Jackson S, Nakamura M. Efficacy of spironolactone in treating hidradenitis suppurativa in women of childbearing age: a single-center retrospective analysis. Int J Womens Dermatol. 2024;10(3):e159. https:\/\/doi.org\/10.1097\/jw9.0000000000000159.","journal-title":"Int J Womens Dermatol."},{"issue":"5","key":"564_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/jdv.19725","volume":"38","author":"P Aarts","year":"2024","unstructured":"Aarts P, van Huijstee JC, van der Zee HH, van Straalen KR, Prens EP. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2024;38(5):904\u20139. https:\/\/doi.org\/10.1111\/jdv.19725.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"564_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-bsgcampus.177","author":"HA Norredinvand","year":"2021","unstructured":"Norredinvand HA, Bishop S, Patel J, Sivanesan N, Fong S. P102 Outcomes of biosimilar adalimumab switchbacks\/reverse switching in IBD: real-world experience. Gut. 2021. https:\/\/doi.org\/10.1136\/gutjnl-2020-bsgcampus.177.","journal-title":"Gut"},{"issue":"4","key":"564_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40259-025-00719-z","volume":"39","author":"JRP Tesser","year":"2025","unstructured":"Tesser JRP, Charabaty A, Hebert AA. Switching from adalimumab reference product to and among adalimumab biosimilars outside the USA: insights for US clinicians. BioDrugs. 2025;39(4):591\u2013606. https:\/\/doi.org\/10.1007\/s40259-025-00719-z.","journal-title":"BioDrugs"},{"issue":"1","key":"564_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12865-025-00693-9","volume":"26","author":"WHA van Poecke","year":"2025","unstructured":"van Poecke WHA, Hooi NEF, Mossel TK, Hermans MAW, van Daele PLA, Bunnik EM, et al. Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study. BMC Immunol. 2025;26(1):44. https:\/\/doi.org\/10.1186\/s12865-025-00693-9.","journal-title":"BMC Immunol"},{"key":"564_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.clindermatol.2023.08.020","volume":"41","author":"Z Bukvi\u0107 Mokos","year":"2023","unstructured":"Bukvi\u0107 Mokos Z, Markota \u010cagalj A, Marinovi\u0107 B. Epidemiology of hidradenitis suppurativa. Clin Dermatol. 2023;41:564\u201375. https:\/\/doi.org\/10.1016\/j.clindermatol.2023.08.020.","journal-title":"Clin Dermatol"},{"issue":"8","key":"564_CR18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1001\/jamadermatol.2019.0478","volume":"155","author":"HB Naik","year":"2019","unstructured":"Naik HB, Paul M, Cohen SR, Alavi A, Su\u00e0rez-Fari\u00f1as M, Lowes MA. Distribution of self-reported hidradenitis suppurativa age at onset. JAMA Dermatol. 2019;155(8):971\u20133. https:\/\/doi.org\/10.1001\/jamadermatol.2019.0478.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"564_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/bjd.17101","volume":"181","author":"T Tzellos","year":"2019","unstructured":"Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J. Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol. 2019;181(1):147\u201354. https:\/\/doi.org\/10.1111\/bjd.17101.","journal-title":"Br J Dermatol"},{"issue":"9","key":"564_CR20","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamadermatol.2018.2117","volume":"154","author":"S Wertenteil","year":"2018","unstructured":"Wertenteil S, Strunk A, Garg A. Association of low socioeconomic status with hidradenitis suppurativa in the United States. JAMA Dermatol. 2018;154(9):1086\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2018.2117.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"564_CR21","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/jdv.20607","volume":"39","author":"M Doroudian Tehrani","year":"2025","unstructured":"Doroudian Tehrani M, Gibson RS, Snyder CL, Porter ML, Kimball AB. Cumulative life course impairment: evidence for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2025;39(8):1395\u2013409. https:\/\/doi.org\/10.1111\/jdv.20607.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"564_CR22","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1186\/1471-2458-10-632","volume":"10","author":"RE Foraker","year":"2010","unstructured":"Foraker RE, Rose KM, Whitsel EA, Suchindran CM, Wood JL, Rosamond WD. Neighborhood socioeconomic status, Medicaid coverage and medical management of myocardial infarction: atherosclerosis risk in communities (ARIC) community surveillance. BMC Public Health. 2010;10:632. https:\/\/doi.org\/10.1186\/1471-2458-10-632.","journal-title":"BMC Public Health"},{"issue":"6","key":"564_CR23","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.jaad.2024.09.027","volume":"91","author":"A Charrow","year":"2024","unstructured":"Charrow A, Santiago-Soltero K, Porter M. Biologics in hidradenitis suppurativa: progress and new directions. J Am Acad Dermatol. 2024;91(6):S27\u201330. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.027.","journal-title":"J Am Acad Dermatol"},{"issue":"10378","key":"564_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(23)00022-3.","journal-title":"Lancet"},{"issue":"10443","key":"564_CR25","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(24)00101-6.","journal-title":"Lancet"},{"issue":"11","key":"564_CR26","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1136\/annrheumdis-2017-211384","volume":"76","author":"ME Clowse","year":"2017","unstructured":"Clowse ME, Forger F, Hwang C, Thorp J, Dolhain RJ, van Tubergen A, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211384.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"564_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","volume":"77","author":"X Mariette","year":"2018","unstructured":"Mariette X, Forger F, Abraham B, Flynn AD, Molto A, Flipo RM, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228\u201333. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212196.","journal-title":"Ann Rheum Dis"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00564-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00564-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00564-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:02:31Z","timestamp":1789394551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00564-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00564-8","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"16 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UCB contributed to study design, participated in data collection, completed the data analysis, and participated in data interpretation. UCB participated in writing, review, and approval of the manuscript. All authors had full access to the data, reviewed, and approved the final version and were responsible for the decision to submit for publication. A medical writing agency, employed by UCB, assisted with manuscript preparation under the authors\u2019 direction.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MAA: Consulting fees from AbbVie and Santa Ana Bio; advisory board for Novartis; research funding from UCB. TT, IP, AS, and DF: Employees and shareholders of UCB. ABK: ABK\u2019s institution received grants from AbbVie, Admirx, AnaptysBio, Aristea, Bristol Myers Squibb, Eli Lilly and Company, Incyte, Janssen, MoonLake Immunotherapeutics, Novartis, Pfizer, Prometheus, Sonoma Biotherapeutics, and UCB; received consulting fees from AbbVie, Alumis, Avalo, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Janssen, MoonLake Immunotherapeutics, Novartis, Pfizer, Priovant, Sanofi, Sonoma Biotherapeutics, Target RWE, UCB, Union Therapeutics, and Ventyx; serves on the board of directors of Almirall.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MAA, TT, IP, AS, DF, and ABK had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Substantial contributions to study conception and design: MAA, TT, IP, AS, DF, and ABK. Substantial contributions to analysis and interpretation of the data: MAA, TT, IP, AS, DF, and ABK. Drafting the article or revising it critically for important intellectual content: MAA, TT, IP, AS, DF, and ABK. Final approval of the version of the article to be published: MAA, TT, IP, AS, DF, and ABK.","order":3,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval was not required as this study utilized deidentified claims data. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Consent from patients for the use of their data in the study and its publication was also not required as this was a retrospective cohort study that used deidentified claims data.","order":4,"name":"Ethics","label":"Ethical Approval and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Underlying data from this manuscript can be requested by qualified researchers 6 months after product approval in the USA and Europe, or global development is discontinued, and 18 months after trial completion. Investigators can request access to anonymized individual patient-level data and redacted trial documents, which can include analysis-ready datasets, study protocol, annotated case-report form, statistical analysis plan, dataset specifications, and clinical study report. Before use of the data, proposals need to be approved by an independent review panel at\n                      \n                      and a signed data-sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password-protected portal.","order":5,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SAS 9.4 and STATA used for coding analysis. This can be requested as per the above statement.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}